-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $19

Benzinga·08/01/2025 15:08:53
Listen to the news
RBC Capital analyst Lisa Walter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and raises the price target from $17 to $19.